BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) posted its earnings results on Monday. The biotechnology company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.27, Briefing.com reports. The company had revenue of $145.53 million during the quarter, compared to analyst estimates of $126.83 million. During the same period in the previous year, the company earned ($0.17) EPS. The company's quarterly revenue was up 56.8% compared to the same quarter last year.

BioCryst Pharmaceuticals Trading Up 0.6 %

BCRX stock traded up $0.06 during trading on Friday, hitting $9.98. 7,606,302 shares of the company's stock were exchanged, compared to its average volume of 2,991,433. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -16.36 and a beta of 1.08. BioCryst Pharmaceuticals has a 52-week low of $5.23 and a 52-week high of $11.11. The business has a 50-day moving average price of $7.87 and a two-hundred day moving average price of $7.89.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BCRX shares. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price on the stock. JPMorgan Chase & Co. lifted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday. Royal Bank of Canada reiterated an "outperform" rating and set a $13.00 target price (up from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday. Evercore ISI boosted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Finally, Barclays increased their price objective on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $16.56.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.